Table 2.

Ongoing studies of metronomic chemotherapy (mCHT)

Study name (ID)	Breast cancer setting	Treatment	Primary endpoint
TEMPO-Breast 01	HR+, HER2− metastatic	Metronomic oral V vs oral V as first-line therapy	Disease control rate
VENTANA (NCT02802748)	Neo-adjuvant	Oral metronomic V + L vs L	Change in the expression of the PAM50 proliferation signature
VICTORIANE (NCT02954055)	Advanced	Metronomic V + E vs V	PFS
METEORA-II (NCT02954055)	ER+, HER2−, metastatic, or locally relapsed	Metronomic V + C + CAPE vs weekly P	TTF
VICTOR-3 (NCT03358004)	Triple-negative	Metronomic V + CAPE vs metronomic CAPE alone as first-line therapy	PFS rate at 12 weeks
MAVERICK (NCT03007992)	HER2−	Metronomic V vs best supportive care	Clinical benefit rate

Abbreviations: −, negative; +, positive; C, cyclophosphamide; CAPE, capecitabine; E, everolimus; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; L, letrozole; P, paclitaxel; PAM50, Prosigna Breast Cancer Prognostic Gene Signature Assay; PFS, progression-free survival; TTF, time to treatment failure; V, vinorelbine.